Bacterial keratitis is a serious and potentially sight-threatening infection of the cornea, the transparent front part of the eye. It is caused by the invasion of bacteria into the corneal tissue, often resulting from corneal trauma, contact lens use, or compromised ocular surfaces. Common bacterial culprits include Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa. Symptoms of bacterial keratitis include eye pain, redness, blurred vision, sensitivity to light, and the sensation of a foreign body in the eye. Timely diagnosis is essential, typically involving a thorough eye examination and corneal cultures. Treatment for bacterial keratitis involves the prompt administration of topical antibiotics specific to the identified bacteria. Severe cases may require additional interventions such as corneal debridement or surgery. Preventive measures include proper contact lens hygiene, avoiding eye trauma, and seeking prompt medical attention for any eye injuries. Prompt and appropriate management is crucial in preventing complications and preserving visual function in cases of bacterial keratitis.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States